New anticonvulsant for Lennox-Gastaut syndrome

Eisai has launched Inovelon (rufinamide) for adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients from four years of age.

Lennox-Gastaut syndrome is a severe form of epilepsy, characterised by onset in early childhood of frequent seizures of multiple types.

Rufinamide is a broad-spectrum anticonvulsant that is structurally distinct from other antiepileptic drugs. It modulates the activity of neuronal sodium channels, prolonging their inactive state. Efficacy against seizures of Lennox-Gastaut syndrome has been demonstrated.

Further information: Eisai 020 8600 1400

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more